Phase 3 CLL/SLL trial of ICP-248 plus orelabrutinib doses first patient
The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia…
The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia…
Orca-T, Orca Bio‘s investigational allogeneic stem cell transplant for treating blood cell cancers, more than doubled the rate of survival free from moderate…
Chromoanagenesis — an abnormal rearrangement of DNA within the chromosomes of certain cells, including blood cells — links with limited treatment response and poorer outcomes…
China has granted breakthrough therapy designation to olverembatinib to be used with low-intensity chemotherapy as a first-line treatment for newly diagnosed people with Philadelphia chromosome-positive…
Aptose Biosciences will be testing a higher dose of tuspetinib as part of a triple-combination regimen that’s being explored in a clinical trial…
A triple-combination therapy using tuspetinib, Aptose Biosciences‘ experimental oral therapy, is showing potential in treating adults with newly diagnosed acute myeloid leukemia (AML),…
Treatment with the cancer vaccine galinpepimut-S (GPS) is showing promise to potentially improve survival in people with acute myeloid leukemia (AML), a type of…
The European Commission has approved Blincyto (blinatumomab) as part of a consolidation therapy regimen to reduce the risk of relapse in adults newly diagnosed…
The U.S. Food and Drug Administration (FDA) has approved Grafapex (treosulfan), an injectable chemotherapy, as part of the drug regimen for adults and…
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) as a treatment for mantle cell lymphoma (MCL), a rare and…